-
Mashup Score: 0Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML - 8 month(s) ago
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FCR plays a crucial role in the curative treatment of a subgroup of patients with CLL and should still be considered for these patients despite the emergence of newer standards of care. @PeterMacCC @TheRMH @SocietyofHemOnc #SOHO2023 #leusm https://t.co/BEmMJ4KNb2 https://t.co/2vp5NpVXbB
-
-
Mashup Score: 1Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma - 8 month(s) ago
Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma @MSKCancerCenter @szusmani @SocietyofHemOnc #SOHO2023 #mmsm https://t.co/4bgbtuz7M7
-
-
Mashup Score: 0
Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML @Daver_Leukemia @MDAndersonNews @SocietyofHemOnc #SOHO2023 #leusm https://t.co/8ZeV04ilHb
-
-
Mashup Score: 0Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML - 8 month(s) ago
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients acute myeloid leukemia and highlights the unmet needs that remain in older and high-risk subgroups within this patient population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Courtney D. DiNardo, MD, MSCE, discusses ongoing investigations of triplet regimens with an azacitidine/venetoclax backbone for the treatment of patients with AML. @mdandersonnews @societyofhemonc #SOHO2023 #leusm https://t.co/K1OgWB9XS1
-
-
Mashup Score: 0Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL - 8 month(s) ago
Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ongoing studies and the recent FDA approval of pirtobrutinib for the treatment of patients with relapsed/refractory MCL could shift how and when BTK inhibitors are used in practice. @WUSTLmed @SocietyofHemOnc #SOHO2023 #lymsm https://t.co/TnmuvLGaIb https://t.co/7ITr3DJh07
-
-
Mashup Score: 0Considerations for CAR T-Cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma - 8 month(s) ago
Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Given its time on the market, there is now real-world data available on the use of axi-cel for patients with relapsed/refractory FL after 2 or more lines of systemic therapy. @SocietyofHemOnc #SOHO2023 #lymsm https://t.co/fgitLyW5Yu https://t.co/ZhAyzQG62s
-
-
Mashup Score: 0
Uwe Platzbecker, MD, discusses the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from ongoing phase 3 clinical trials could continue to alter the treatment landscape for patients with lower-risk myelodysplastic neoplasms, according to Uwe Platzbecker, MD. @SocietyofHemOnc #mpnsm #SOHO2023 https://t.co/Ax40uFEKPd https://t.co/Ps2CZonzOt
-
-
Mashup Score: 0Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL - 8 month(s) ago
Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ongoing Research Aims to Address Further Questions on Fixed-Duration Therapy in CLL @MDAndersonNews #SOHO2023 #leusm https://t.co/COxZme6ITP
-
-
Mashup Score: 0
Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The myelofibrosis treatment landscape continues to grow with the approvals of ruxolitinib, fedratinib, and pacritinib, and an FDA review is planned for momelotinib in September 2023. @SocietyofHemOnc #SOHO2023 #mpnsm #hematology https://t.co/s278hEowaS
-
Although azacitidine and venetoclax has become a standard of care in AML, triplet therapies built off this backbone could improve outcomes and address unmet needs for subsets of patients. @mdandersonnews @societyofhemonc #SOHO2023 #leusm https://t.co/K1OgWB9XS1 https://t.co/NylHJS8YfB